论文部分内容阅读
[目的]观察巴曲酶对急性脑梗死的疗效。[方法]将78例急性脑梗塞患者随机分为2组,治疗组d1用巴曲酶10BU,d3和d5用5BU,加入0.9%生理盐水250ml静滴。对照组用苦蝶子注射液40ml加入0.9%生理盐水250ml静滴,每日1次,14d为1疗程。观察治疗前后神经功能缺损评分的变化,以及不同溶栓时间的疗效。[结果]巴曲酶组(治疗组)总有效率90.0%,明显高于对照组(P﹤0.01)。治疗组发病在24h内用药和至3d用药的总有效率接近,但基本治愈率和显效率则差异有统计学意义(P﹤0.05)。[结论]巴曲酶治疗脑梗死安全有效,且用药越早,疗效愈好。
[Objective] To observe the curative effect of batroxobin on acute cerebral infarction. [Methods] A total of 78 patients with acute cerebral infarction were randomly divided into 2 groups. The treatment group received baicalin 10BU for d1, 5BU for d3 and d5, and 250ml 0.9% saline for intravenous infusion. The control group with Sophora injection 40ml added 0.9% saline 250ml intravenous infusion, once daily, 14d for a course of treatment. Changes in neurological deficit scores before and after treatment, as well as the efficacy of different thrombolytic time were observed. [Results] The total effective rate of Batroxobin group (treatment group) was 90.0%, which was significantly higher than that of control group (P <0.01). The total effective rate of the treatment group within 24 hours of medication and until the 3d medication was similar, but the difference between the basic cure rate and the markedly effective rate was statistically significant (P <0.05). [Conclusion] Batroxobin is safe and effective in the treatment of cerebral infarction, and the earlier the treatment, the better the curative effect.